Now showing 1 - 7 of 7
  • 2022Journal Article Research Paper
    [["dc.bibliographiccitation.journal","Frontiers in Microbiology"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Taverne-Ghadwal, Liliane"],["dc.contributor.author","Kuhns, Martin"],["dc.contributor.author","Buhl, Timo"],["dc.contributor.author","Schulze, Marco H."],["dc.contributor.author","Mbaitolum, Weina Joseph"],["dc.contributor.author","Kersch, Lydia"],["dc.contributor.author","Weig, Michael"],["dc.contributor.author","Bader, Oliver"],["dc.contributor.author","Groß, U."],["dc.date.accessioned","2022-04-01T10:00:45Z"],["dc.date.available","2022-04-01T10:00:45Z"],["dc.date.issued","2022"],["dc.description.abstract","Oral candidiasis remains a common problem in HIV-infected individuals, especially in sub-Saharan Africa. Here, we performed the first study in Chad on the prevalence of oral yeasts carriage and oral candidiasis in HIV-positive subjects from southern Chad and analyzed the influence of HAART, CD4 + T-cell numbers, and antimycotics in 589 patients. These patients were recruited from a specialized medical center for HIV patients in Sarh and from a rural medical health dispensary in the vicinity, including a total of 384 HIV-positive and 205 HIV-negative individuals. Yeasts obtained from oral specimen were identified by MALDI-TOF MS and their antifungal susceptibility profiles determined. The overall prevalence of yeast colonization and symptomatic oral candidiasis in HIV-infected patients was 25.1%. The prevalence of oral candidiasis was higher in untreated than in HAART-treated HIV-positive patients (16% vs. 2%; p  < 0.01). Oral candidiasis was furthermore associated with high fungal burdens of Candida albicans and a CD4 + T-cell number <200/μl. A shift toward non -albicans Candida species was observed under nucleoside-based HAART therapy. Azole antifungal drug resistance was only observed for the intrinsically resistant species Candida krusei and Candida glabrata . Prevalence of oral candidiasis in the studied area was very low. The species distribution was similar to other countries around the world, with C. albicans being dominant. Candida dubliniensis was not isolated. Nucleoside-based HAART therapy significantly reduced oral colonization as well as occurrence of oral candidiasis caused by C. albicans and led to a species shift toward non- albicans species. Antifungal resistance was not yet a concern in Chad."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.3389/fmicb.2022.844069"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105503"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1664-302X"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Epidemiology and Prevalence of Oral Candidiasis in HIV Patients From Chad in the Post-HAART Era"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]
    Details DOI
  • 2015Journal Article
    [["dc.bibliographiccitation.artnumber","33"],["dc.bibliographiccitation.journal","Annals of Clinical Microbiology and Antimicrobials"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Kunze, Nils"],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Steinmetz, Nicolas"],["dc.contributor.author","Schulze, M. H."],["dc.contributor.author","Quintel, Michael"],["dc.contributor.author","Perl, Thorsten"],["dc.date.accessioned","2018-11-07T09:55:53Z"],["dc.date.available","2018-11-07T09:55:53Z"],["dc.date.issued","2015"],["dc.description.abstract","Background: The early beginning of an adequate antibiotic therapy is crucial in hospital-acquired pneumonia (HAP), but depends on the results of conventional microbiological diagnostics (cMD). It was the aim of this study to evaluate the performance and turnaround times of a new point-of-care multiplex polymerase chain reaction (mPCR) system for rapid identification of pathogens and antibiotic resistance markers. We assessed the applicability of the system under real-life conditions in critical ill patients with HAP. Methods: We enrolled forty critical ill patients with clinical signs for HAP into an observational study. Two samples of respiratory secretions were collected during one course of aspiration and cMD and mPCR testing (Unyvero, Curetis AG, Holzgerlingen, Germany) were performed immediately. The mPCR device was operated as a point-of-care system at the intensive care unit. We compared turnaround times, results of pathogen identification and results of antibiotic resistance testing of both methods. Results: Mean turnaround times (min-max) were 6.5 h (4.7-18.3 h) for multiplex PCR and 71 h (37.2-217.8 h) for conventional microbiology (final cMD results, incomplete results neglected). 60 % (n = 24) of the mPCR tests were completely valid. Complete test failure occurred in 10 % (n = 4) and partial test failure occurred in 30 % (n = 12). We found concordant results in 45 % (n = 18) and non-concordant results in 45 % (n = 18) of all patients. 55 % (n = 16) of the results were concordant in patients with a clinical pulmonary infection score (CPIS) > 5 (n = 29). Concordant results included three cases of multidrug resistant bacteria. MPCR frequently detected antibiotic resistance markers that were not found by cMD. Conclusions: Unyvero allowed point-of-care microbial testing with short turnaround times. The performance of the system was poor. However, an improved system with a more reliable performance and an extended microbial panel could be a useful addition to cMD in intensive care medicine."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2015"],["dc.identifier.doi","10.1186/s12941-015-0091-3"],["dc.identifier.isi","000356592600001"],["dc.identifier.pmid","26071191"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13460"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36848"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prĂĽfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1476-0711"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Point-of-care multiplex PCR promises short turnaround times for microbial testing in hospital-acquired pneumonia - an observational pilot study in critical ill patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC WOS
  • 2014Journal Article
    [["dc.bibliographiccitation.firstpage","59"],["dc.bibliographiccitation.journal","International Journal of Infectious Diseases"],["dc.bibliographiccitation.lastpage","64"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Grau, Imma"],["dc.contributor.author","Ardanuy, Carmen"],["dc.contributor.author","Calatayud, Laura"],["dc.contributor.author","Schulze, M. H."],["dc.contributor.author","Linares, Josefina"],["dc.contributor.author","Pallares, Roman"],["dc.date.accessioned","2018-11-07T09:36:51Z"],["dc.date.available","2018-11-07T09:36:51Z"],["dc.date.issued","2014"],["dc.description.abstract","Objectives: To determine the prevalence of smoking and alcohol abuse among patients with invasive pneumococcal disease (IPD) in order to promote prevention strategies. Methods: We prospectively studied all culture-proven IPD cases in patients aged >= 18 years during the period 1997-2011. The habits of smoking and alcohol abuse were evaluated. Pneumococcal serotyping was performed. Results: There were 1378 IPD cases, with a mean age of 61 +/- 17 years; 65% were males. Compared to the general population aged 18-64 years, patients with IPD of the same age group were more often current smokers (57% vs. 35%, p < 0.001) and alcohol abusers (21% vs. 6%, p < 0.001). Among patients with IPD, young adults (aged 18-49 vs. 50-64 vs. >= 65 years) were more commonly current smokers (71% vs. 40% vs. 14%, p < 0.001) and alcohol abusers (23% vs. 18% vs. 6%, p < 0.001). Males were more frequently smokers and alcohol abusers than females. Smokers and alcohol abusers more often had underlying diseases such as HIV infection and chronic liver disease. Pneumonia was more common in smokers and peritonitis in alcohol abusers. Alcohol abuse conferred higher mortality. Certain pneumococcal serotypes, such as serotypes 1, 8, and 23F, more frequently caused IPD in smokers, and serotypes 4, 11A, and 19F in alcohol abusers. Conclusions: Smoking and alcohol abuse are the most preventable risk factors for IPD. Implementing smoking and alcohol abuse cessation programs and a pneumococcal vaccination schedule are essential to diminish the burden of pneumonia and other pneumococcal infections. (C) 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. All rights reserved."],["dc.identifier.doi","10.1016/j.ijid.2013.12.013"],["dc.identifier.isi","000343815700012"],["dc.identifier.pmid","24853638"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11303"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32706"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prĂĽfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Sci Ltd"],["dc.relation.issn","1878-3511"],["dc.relation.issn","1201-9712"],["dc.rights","CC BY-NC-SA 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-sa/3.0"],["dc.title","Smoking and alcohol abuse are the most preventable risk factors for invasive pneumonia and other pneumococcal infections"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC WOS
  • 2014-10-01Journal Article
    [["dc.bibliographiccitation.firstpage","191"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Clinical case reports"],["dc.bibliographiccitation.lastpage","196"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Schulze, Marco H."],["dc.contributor.author","Raschel, Heribert"],["dc.contributor.author","Langen, Heinz-Jakob"],["dc.contributor.author","Stich, August"],["dc.contributor.author","Tappe, Dennis"],["dc.date.accessioned","2019-07-09T11:41:21Z"],["dc.date.available","2019-07-09T11:41:21Z"],["dc.date.issued","2014-10-01"],["dc.description.abstract","KEY CLINICAL MESSAGE: The traditional concept of immediate antibiotic treatment in suspected leptospirosis seems to be especially important for patients up to day 4 of clinical illness. As immune mechanisms probably play a crucial role in advanced leptospirosis with presumed pulmonary hemorrhages, patients might benefit from corticosteroids or other immunosuppressive agents beside antibiotics."],["dc.identifier.doi","10.1002/ccr3.91"],["dc.identifier.pmid","25614810"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11989"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58410"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2050-0904"],["dc.rights","CC BY-NC-ND 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/3.0"],["dc.title","Severe Leptospira interrogans serovar Icterohaemorrhagiae infection with hepato-renal-pulmonary involvement treated with corticosteroids."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC
  • 2011-10-01Journal Article
    [["dc.bibliographiccitation.firstpage","1879"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Emerging infectious diseases"],["dc.bibliographiccitation.lastpage","1882"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","GroĂź, Uwe"],["dc.contributor.author","Amuzu, Sylvarius K."],["dc.contributor.author","Ciman, Ring de"],["dc.contributor.author","Kassimova, Iparkhan"],["dc.contributor.author","GroĂź, Lisa"],["dc.contributor.author","Rabsch, Wolfgang"],["dc.contributor.author","Rosenberg, Ulrike"],["dc.contributor.author","Schulze, Marco"],["dc.contributor.author","Stich, August"],["dc.contributor.author","Zimmermann, Ortrud"],["dc.date.accessioned","2021-11-22T14:31:53Z"],["dc.date.available","2021-11-22T14:31:53Z"],["dc.date.issued","2011-10-01"],["dc.description.abstract","Bacterial distribution and antimicrobial drug resistance were monitored in patients with bacterial bloodstream infections in rural hospitals in Ghana. In 2001-2002 and in 2009, Salmonella enterica serovar Typhi was the most prevalent pathogen. Although most S. enterica serovar Typhi isolates were chloramphenicol resistant, all isolates tested were susceptible to ciprofloxacin."],["dc.description.sponsorship","Bayer Social Health Care Programs"],["dc.identifier.doi","10.3201/eid1710.110327"],["dc.identifier.fs","583995"],["dc.identifier.isi","000295897300014"],["dc.identifier.pmid","22000360"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7833"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/93412"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21848"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.notes.status","zu prĂĽfen"],["dc.notes.submitter","Najko"],["dc.publisher","Centers Disease Control"],["dc.relation.issn","1080-6059"],["dc.rights.access","openAccess"],["dc.subject","Ghana; bacterial distribution; drug resistance"],["dc.subject.mesh","Adult"],["dc.subject.mesh","Anti-Bacterial Agents"],["dc.subject.mesh","Bacteremia"],["dc.subject.mesh","Drug Resistance, Bacterial"],["dc.subject.mesh","Ghana"],["dc.subject.mesh","Humans"],["dc.subject.mesh","Microbial Sensitivity Tests"],["dc.subject.mesh","Middle Aged"],["dc.subject.mesh","Salmonella enterica"],["dc.subject.mesh","Time Factors"],["dc.subject.mesh","Typhoid Fever"],["dc.subject.mesh","Young Adult"],["dc.title","Bacteremia and antimicrobial drug resistance over time, Ghana."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC WOS
  • 2021Journal Article Research Paper
    [["dc.bibliographiccitation.firstpage","537"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Microorganisms"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Monnheimer, Mathieu"],["dc.contributor.author","Cooper, Paul"],["dc.contributor.author","Amegbletor, Harold K."],["dc.contributor.author","Pellio, Theresia"],["dc.contributor.author","GroĂź, Uwe"],["dc.contributor.author","Pfeifer, Yvonne"],["dc.contributor.author","Schulze, Marco H."],["dc.date.accessioned","2021-04-14T08:27:53Z"],["dc.date.available","2021-04-14T08:27:53Z"],["dc.date.issued","2021"],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.3390/microorganisms9030537"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82438"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","2076-2607"],["dc.relation.orgunit","Institut fĂĽr Krankenhaushygiene und Infektiologie"],["dc.rights","CC BY 4.0"],["dc.title","High Prevalence of Carbapenemase-Producing Acinetobacter baumannii in Wound Infections, Ghana, 2017/2018"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]
    Details DOI
  • 2022Journal Article Research Paper
    [["dc.bibliographiccitation.firstpage","150"],["dc.bibliographiccitation.journal","International Journal of Infectious Diseases"],["dc.bibliographiccitation.lastpage","159"],["dc.bibliographiccitation.volume","119"],["dc.contributor.author","Dudakova, Anna"],["dc.contributor.author","Blei, Claudia"],["dc.contributor.author","Groß, Uwe"],["dc.contributor.author","Schulze, Marco H."],["dc.date.accessioned","2022-12-01T08:30:37Z"],["dc.date.available","2022-12-01T08:30:37Z"],["dc.date.issued","2022"],["dc.description.abstract","Background: Candidemia is rare and has a high mortality rate. This study analyses the impact of bedside antifungal stewardship (AFS) on clinical management and prognosis of patients with candidemia at a university hospital in Germany. Methods: All patients with at least one positive blood culture with Candida species between 2014 and 2016 received bedside AFS with standardized recommendations. Medical records were retrospectively an- alyzed. Results from the intervention period from 2014-2016 (n=109), with focus on 2016 (n=39), were compared with those from the pre-intervention period in 2013 (n=30). Results: Bedside AFS was performed in 24/35 (69%) surviving patients in 2016 within the first 3 days after diagnosis of candidemia. All surviving patients (n=35) in 2016 received antifungal treatment compared with 24/28 (86%) in 2013 (p=0.0344). Follow-up blood cultures were performed in 25/35 (71%) in 2016 compared with 10/25 (40%) in 2013 (p=0.0046). Survival in the intervention compared with the pre- intervention group did not differ significantly (p=0.58) one year after the diagnosis of candidemia was made. However, patients with candidemia often have multiple serious comorbidities. Conclusions: Individualized bedside AFS significantly improves adherence to recommendations for pa- tients with Candida fungemia, especially guideline-oriented diagnostics and therapy. Improving the prog- nosis of patients with candidemia remains a huge challenge for AFS."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.1016/j.ijid.2022.03.054"],["dc.identifier.pii","S1201971222001916"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/117935"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.issn","1201-9712"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://www.elsevier.com/tdm/userlicense/1.0/"],["dc.title","Impact of routine bedside infectious diseases service on clinical management and prognosis of patients with Candida fungemia – an example for Antifungal Stewardship at university level in Germany"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]
    Details DOI